Table 2 Incidences and hazard ratios for risks of PE, PAOD, and DVT in recipients of various ADT treatment for prostate cancer.

Control

37

22811

1.62

Ref.

ADT overall

92

32021

2.87

2.11 (1.33–3.36)**

   Surgical castration

2

1219

1.64

0.96 (0.23–4.02)

   Anti-androgen

51

18209

2.80

2.17 (1.30–3.62)**

   Chemical castration

39

12592

3.10

2.27 (1.32–3.89)**

     GnRH agonist alone

4

2504

1.60

1.30 (0.45–3.77)

     CAB

35

10089

3.47

2.53 (1.45–4.42)**

   Total castration

41

13811

2.97

2.06 (1.23–3.46)**

     ≤180 days

5

1152

4.34

2.78 (1.00–7.72)*

     181–720 days

17

5882

2.89

2.16 (1.12–4.17)*

     >720 days

17

5558

3.06

2.29 (1.17–4.50)*

     ≤720 days

22

7034

3.13

2.28 (1.24–4.19)**

     >720

17

5558

3.06

2.31 (1.17–4.53)*

Control

12

22896

0.52

Ref.

ADT overall

32

32158

1.00

2.10 (0.94–4.72)

   Surgical castration

0

1230

0.00

NA

   Anti-androgen

18

18295

0.98

2.25 (0.91–5.60)

     Chemical castration

14

12634

1.11

2.51 (0.97–6.46)

       GnRH agonist alone

0

2515

0.00

NA

      CAB

14

10119

1.38

3.11 (1.19–8.16)*

   Total castration

14

13863

1.01

2.07 (0.85–5.05)

   ≤180 days

1

1155

0.87

2.59 (0.30–22.2)

   181–720 days

7

5902

1.19

3.27 (1.09–9.76)*

   >720 days

6

5576

1.08

1.95 (0.61–6.22)

   ≤720 days

8

7058

1.13

3.16 (1.10–9.07)*

   >720

6

5576

1.08

1.95 (0.61–6.19)

Control

16

22887

0.70

Ref.

ADT overall

33

32103

1.03

1.01 (0.53–1.92)

   Surgical castration

0

1230

0.00

NA

   Anti-androgen

22

18267

1.20

1.17 (0.59–2.34)

   Chemical castration

11

12606

0.87

0.84 (0.38–1.89)

      GnRH agonist alone

0

2515

0.00

NA

      CAB

11

10092

1.09

1.01 (0.45–2.30)

      Total castration

11

13836

0.80

0.78 (0.35–1.75)

   ≤180 days

1

1154

0.87

1.26 (0.15–10.3)

   181–720 days

4

5894

0.68

0.71 (0.23–2.21)

   >720 days

6

5558

1.08

0.91 (0.34–2.48)

   ≤720 days

5

7049

0.71

0.78 (0.27–2.21)

   >720

6

5558

1.08

0.92 (0.34–2.49)